載入...
Comparative effectiveness of approved first-line anti-angiogenic and molecularly targeted therapeutic agents in the treatment of good and intermediate risk metastatic clear cell renal cell carcinoma
BACKGROUND: Based on improved clinical outcomes in randomized controlled clinical trials (RCTs) the FDA and EMA have approved bevacizumab with interferon, sunitinib, and pazopanib in the first-line treatment of low to intermediate risk metastatic clear cell renal cell carcinoma (mRCC). However, ther...
Na minha lista:
| Main Authors: | , , , , |
|---|---|
| 格式: | Artigo |
| 語言: | Inglês |
| 出版: |
BioMed Central
2014
|
| 主題: | |
| 在線閱讀: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4148555/ https://ncbi.nlm.nih.gov/pubmed/25127891 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/1471-2407-14-592 |
| 標簽: |
添加標簽
沒有標簽, 成為第一個標記此記錄!
|